Dr Simon Gollins is a Consultant Clinical Oncologist based at The North Wales Cancer Treatment Centre, Glan Clwyd.

Dr Gollins qualified in medicine in 1988 at the University of Oxford, where he also carried out 3 years of laboratory research for a Doctor of Philosophy degree (PhD). Following medical jobs in Bath and Birmingham he gained his Membership of the Royal College of Physicians in 1991.

His oncology training took place at the Christie Hospital Manchester where he gained his Fellowship of the Royal College of Radiologists in 1994 and at Velindre Hospital Cardiff where he was also a Consultant Clinical Oncologist prior to moving to North Wales.

Dr Shankara Paneesha is a Consultant Haematologist based at The Heart of England NHS Foundation Trust in Birmingham.

Dr Paneesha also consults at Spire Little Aston & Spire Parkway Hospitals.

He graduated from Mysore University in 1993 and obtained postgraduate qualification in General Medicine from Bombay University in 1996.

He completed specialist training in hematology from the West Midlands Deanery following initial training at the Royal Free and the Royal Marsden Hospitals in London.  He undertook a period of research in myeloma and venous thrombosis at Warwick University. He has an excellent experience in the treatment of hematological malignancies including leukemia, lymphoma, and myeloma, investigation of thrombosis risk factors and inherited thrombophilia and stem cell transplantation. 

He was appointed as a Consultant hematologist in March 2007 at the Heart of England NHS Foundation Trust. His main interests are malignant hematology, Stem Cell Transplantation and venous thrombosis. He has published research in top international hematology journals.

He takes part in a large number of trials in Haemato-oncology either as a principal investigator or as co-investigator at his institution.

Dr Shan Chetiyawardana is a Consultant Clinical Oncologist based at Queen Elizabeth Hospital in Birmingham.

Dr Chetiyawardana has been in post as a Consultant Oncologist at the Queen Elizabeth since 1983, providing oncology services including radiotherapy, chemotherapy, hormone therapy and targeted therapy for breast, lung and urological tumours at Walsall Manor and Queens Hospital, Burton. He conducts seven clinics and attend 6 MDT per week. 

Dr Chetiyawardana is the service lead for Radiotherapy and Chairman of the Oncology Executive Committee at University Hospital Birmingham. He is also the Honorary Senior lecturer at Birmingham University, and a member of the MAC at Spire Little Aston Hospital and lead clinician for Cancer at Spire Little Aston.

Dr Chetiyawardana is a member of Royal College of Radiologists and the International Association for Lung Cancer.

Dr Saifee Mullamitha is a Consultant Medical Oncologist based at The Christie NHS Foundation Trust.

Dr Mullamitha graduated from the University of Bombay in 1995.  He has a dedicated specialist interest in the personalised management of early and advanced colorectal cancer. He is a lead principal investigator and co-investigator in a number of national as well as international clinical trials. Dr Mullamitha collaborates with a number of colleagues, especially liver surgeons and in areas where cyberknife might be a possibility. He has an interest in the liver directed approach e.g. selective internal radiotherapy (SIRT), irinotecan beads (DEBIRI), etc.

Mr Robert Ashford is a Consultant Orthopaedic and Musculoskeletal Tumour Surgeon based at The University Hospitals of Leicester.

Mr Ashford graduated from the London Hospital Medical College in 1992.  He undertook basic surgical training in London and East Anglia and he continued his Orthopaedic training in Leicester and Yorkshire.  After passing the FRCS (Tr. & Orth.) in 2004, he completed a one-year fellowship in Sydney, Australia under Dr Paul Stalley, a world-renowned sarcoma surgeon. He completed a further one-year fellowship in lower limb joint reconstruction and tumour surgery at the Royal National Orthopaedic Hospital, Stanmore.  

He was appointed as a Consultant Orthopaedic and Musculoskeletal Tumour Surgeon at University Hospitals of Leicester NHS Trust and the East Midlands Sarcoma Service in 2007. Mr Ashford has extensive experience in the treatment of a wide variety of hip and knee conditions, bone and soft tissue tumours and trauma. Mr Ashford has published extensively in these fields. He has been awarded an MD for his thesis entitled "Improving the patient journey in breast cancer metastatic to the skeleton" by the University of Sheffield. Mr Ashford is Network Lead Clinician for the East Midlands Sarcoma Service. 

He was selected by the British Orthopaedic Association for the 2014 American-British-Canadian Traveling Fellowship. The ABC Fellowship is a prestigious, highly competitive and sought-after honour awarded to leaders in the field of orthopaedic surgery. ABC Fellows are chosen every two years and travel to various academic institutions in the United States and Canada. They present their research and act as international ambassadors for the BOA as they learn about healthcare and research in their host countries. Mr Ashford is the first Leicester Surgeon to be named an ABC Fellow.

Dr Richard Welch is a Consultant Clinical Oncologist based at The Christie NHS Foundation Trust in Manchester.

Dr Welch studied Medicine at Birmingham University obtaining MBChB in 1983. He trained in Clinical Oncology receiving his Specialist Qualification in 1996.

Richard is the Lead clinician for female germ cell tumours at The Christie with a wide experience of chemotherapy. In addition he has over 10 years experience as Chair for Christie Drugs and Therapeutics committee for The Christie.

Dr Welch has had a significant input into oncology services in Bolton NHS, breast ovary, testicular cancer and acute oncology . 

He has Published and Contributed to many accredited Publications including:

‘outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, pertioneum, and fallopian tube.’ (Jan 2011) : ‘The management of poor prognosis tertoma.’ (March 2010) : ‘SCOTROC 2B: feasibilty of carboplatin followed by doxetaxel-irinotecan as first-line therapy for ovarian cancer’ (Jan 2006) : ‘Stage- and CA125- related survival in patients with epithlial overian cancer treated at a cancer centre.’ (2006) and many more.

Dr Richard Griffiths is a Consultant Medical Oncologist based at The Clatterbridge Cancer Centre in The Wirral.  He is also an Honorary Clinical Lecturer at The University of Liverpool.

Dr Griffiths graduated from The University of Liverpool in 1998 and trained in Medical Oncology at The Christie in Manchester. His PhD thesis at The University of Manchester was on immunotherapy for kidney cancer.  In 2010 he Joined The Clatterbridge Cancer Centre where he maintains an active research interest. 

As a medical oncologist, Dr Griffiths specialises in drug treatments for cancer. His areas of interest are kidney, lung and 'unknown primary' cancers. Dr Griffiths has an interest in clinical research and is the principle investigator on a number of phase II and III clinical trials at Clatterbridge. 

Dr Rai Gattamaneni is a Consultant Clinical Oncologist based at The Christie NHS Foundation Trust in Manchester.

Dr Gattamaneni obtained his medical degree in 1973 and joined The Christie in 1976. His clinical interests are radiotherapy treatment of primary and secondary tumours of the brain and the treatment of cancer in young adults via The Young Oncology Unit at The Christie.

Dr Gattamaneni is a member of the Paediatric multidisciplinary team (MDT) at Royal Manchester Children's Hospital and the Endocrine and Neuro-Oncology MDTs at The Christie.

Dr Gattamaneni sees private patients at The Christie Clinic and is currently on the research team undertaking in phase II and Phase III trials in sarcoma.

Dr Gattamaneni speaks English, Hindu/Urdu, and Telugu.

Mr Rajesh Shah is a Consultant Thoracic Surgeon based at Universtiy Hospital South Manchester NHS Foundation Trust.

Mr Shah is specialty lead in thoracic surgery at UHSM and he trained in Bombay, following on to the UK where he underwent post graduate training in cardiothoracic surgery in Birmingham, Edinburgh and Yorkshire. In 2003 he was appointed as a consultant thoracic surgeon at UHSM and more recently has been the clinical lead for thoracic surgery.

Mr Shah is the programme director & chair of the North West Cardiothoracic Training Committee and he is an examiner of MRCS / FRCS (C/Th). Mr Shah is also the trustee of the SCTS executive committee and part of the faulty standard setting committee intercollegiate board. Mr Shah is also an elected representative and the education secretary for the Society for Cardiothoracic Surgery of GB and Ireland.

Dr Raffaele Califano is a Consultant Medical Oncologist based at The Christie NHS Foundation Trust in Manchester.

Dr Califano has a special interest in thoracic malignancies and clinical cancer research and he is an active member of the Manchester Lung Cancer Group.

He graduated in Medicine and Surgery, summa cum laude, from the University of Perugia (Italy) in 2003 and completed his Specialist Training in Medical Oncology in 2007. From 2008 to 2012, Dr Califano worked as Clinical Research Fellow with the Lung and Melanoma Team at The Christie where he trained in advanced trial design and management. Dr Califano has been an investigator for several phase I-III clinical trials in Lung Cancer and Melanoma, developing a particular interest for molecularly-driven clinical trials in advanced Non-Small Cell Lung Cancer and Small Cell Lung Cancer.

Dr Califano serves as Chairman of the Young Oncologists Committee of the European Society of Medical Oncology (ESMO) and he is a member of the ESMO Educational Committee Steering Group. He is also a member of British Thoracic Oncology Group (BTOG) and International Association of Study of Lung Cancer (IASLC)

Dr Califano is the author of several papers published in indexed peer-reviewed international journals, he acts as peer reviewer for a number of medical journals and he has been an invited speaker to several national and international oncology meetings.